Skubitz, Keith M <br/><br/>
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in mesothelioma.  [electronic resource] 

 -  Cancer investigation  2002 
 - 693-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>0735-7907 
<br/><br/><label>Standard No.: </label>10.1081/cnv-120003538  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Female<br/>Humans<br/>Liposomes<br/>Male<br/>Mesothelioma--drug therapy<br/>Middle Aged<br/>Mouth Mucosa--pathology<br/>Peripheral Nervous System Diseases--chemically induced<br/>Peritoneal Neoplasms--drug therapy<br/>Pleural Neoplasms--drug therapy<br/>Stomatitis--chemically induced<br/>Treatment Outcome